Roche Says EU Approves Avastin for Lung Cancer
罗氏宣布欧盟批准阿瓦斯丁用于治疗肺癌
ZURICH (Reuters) Aug 24 - The European Union has approved Roche's Avastin for use in patients with advanced non-small-cell lung cancer (NSCLC), the Swiss drugmaker said on Friday.
苏黎世(路透社)8月24日-瑞士制药公司罗氏于周五宣布,欧盟已经批准该公司产品阿瓦斯丁用于治疗晚期非小细胞肺癌(NSCLC)。
The approval had been expected following a recommendation in NSCLC cell lung cancer from an EU expert body in July. Avastin already has U.S. approval in the indication.
在欧盟专家组于7月建议该药物用于NSCLC以来,罗氏就一直在等待这一批准。此前,阿瓦斯丁在美国已经获得批准用于非小细胞肺癌。
The approval was for both 7.5 milligram and 15 milligram doses. Data have previously shown a half dose of Avastin was equally as effective as the normal dose in slowing tumour growth in patients with advanced lung cancer.
此次批准的是两种剂量,分别是7.5mg和15mg。数据显示半剂量与常规剂量阿瓦斯丁用于缓解晚期肺癌肿瘤生长的效果相同。
Avastin was originally approved to treat colon cancer, but is now also used to treat breast cancer as well as lung cancer.
最初,阿瓦斯丁批准用于治疗结肠癌,目前也可以用于治疗乳腺癌和肺癌。